The Cell and Gene Therapy Catapult (CGT Catapult) and Deep Science Ventures have partnered to address barriers in the ATMP industry, create new companies and deliver better patient outcomes.
Recent advances in cell and gene therapies promise potential cures to devastating diseases. However, major hurdles still need to be overcome, including ensuring target specificity and effective manufacturing at scale. This collaboration will leverage Deep Science Ventures’ novel outcome-focused approach to venture creation, which combines available scientific knowledge and scientists into high-impact ventures. CGT Catapult will provide its cell and gene therapy-specific technical, non-clinical and regulatory expertise to apply DSV’s approach to the ATMP sector.
Kerstin Papenfuss, Associate Director Pharma at DSV, said: “Joining forces with the CGT Catapult enables us to bring our unique approach to innovation to the cell and gene therapy ecosystem. Bringing together DSV’s structured approach to venture creation and the ability to tap into the CGT Catapult’s network of expertise will allow us to create high-impact solutions overcoming some of the barriers holding back the ATMP space.”
Matthew Durdy, CEO of CGT Catapult, said: “The innovative and collaborative concept used by DSV fits well with the CGT Catapult’s ethos and by addressing challenges within the cell and gene therapy industry, our activities have the potential to provide exceptional outcomes in driving innovation forward and creating opportunities in employment. We very much look forward to initiating our work together and creating new partnerships between scientists and investors.”
